GenoFocus, Inc. engages the research and development of technologies related to biochemical and biotechnology industry. Its products include enzymes for food, animal, bioconversion and edible vaccines. In addition, It also provides technical services such as library generation, high-throughput screening and consulting services. The company was founded by Pan Jae-Gu, Choi Soo-Geun and Jung Heung-Chae on March 29, 2000 and is headquartered in Daejeon, South Korea.

May Sunshine Biotechnology (Zhejiang) Co., Ltd., established on 2019-04-16, Business scope includes general items:grain planting;Retailing of Edible Agricultural Products;Sporting Goods and Equipment Retailing;Cosmetics Retail;Clothing and apparel retail;Personal Hygiene Sales;Daily necessities sales;Retailing of computer software, hardware and auxiliary equipment;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:food sales;Grain Processed Food Production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).The following limited branch operations:licensed items:wine production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Savient Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

Manufactures and markets fermentation raw materials and natural finished products

The Research Institute at Nationwide Children's Hospital is one of America's ten largest free-standing pediatric research centers and works to enhance the health of children by engaging in research.

Shanghai Yuhua Life Technology Development Co., Ltd., established on 2006-02-06, Business scope includes technology development in the field of biotechnology,technical consulting,Technical Services;cosmetic,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals)development,Sales;Engaged in the import and export of goods and technology,food sales. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system (CNS). It is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia.

Shenzhen Siyomicro Bio-Tech Co., Ltd. is a Chinese company. The firm engages in the production of microbial enzymes and small molecular substances.

Kairui Hengji Biomedical (Hangzhou) Co., Ltd., established on 2019-09-23, Business scope includes technology development,technical consulting,Achievement transfer:medical technology,bioengineering technology;Import and export of goods and technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Part of Instituto Hisp��nico del Arroz SA, Fitoplancton Marino SL is a company headquartered in El Puerto, Spain, that engages in marine microalgae production.

Beijing Heyilin Biotechnology Co., Ltd., established on 2017-04-13, The scope of business includes the sale of food;Internet information service;technology development,technology transfer,Technology Promotion,Technical Services;Basic software service;Application software service;Computer System Services;buisness planning;marketing;Conference Services;Undertake exhibition and display activities;sell cosmetics,electronic product,furniture,daily necessities,crafts,Clothing and shoes,household appliances,knitted goods,stationery,sporting goods.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Internet information service,Sale of food and items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Manufactures auto injectors, syringes

TCI Co., Ltd. engages in the research, development, manufacturing, and sales of health foods and care products. The firm's products include function drinks for beauty, slim, health and energy, function foods in double-layered tablets, capsules, microencapsulated beads and sachet, cosmetics and care products, including creams, bio-cellulose masks, sprays and mousses, and dietary supplements. It operates through the following geographical segments: Taiwan, Asia, and Other. The company was founded on August 22, 1980 and is headquartered in Taipei, Taiwan.

LTT Bio-Pharma Co. Ltd. engages in the research and development of drugs and new technologies. It also provides pharmaceuticals through drug delivery systems technology which delivers a required amount of drugs to the target site at the expected time; drug discovery; and dispensing pharmacy services. The company was founded by Yutaka Mizushima on April 1988 and is headquartered in Tokyo, Japan.

Hangzhou Ruidao Pharmaceutical Technology Co., Ltd., established on 2016-06-22, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;R&D of industrial enzyme preparations;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Cosmetics Wholesale;Cosmetics Retail;Sales of hygiene products and single-use medical products;brand management(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Class III medical device business;Food Internet Sales(Selling prepackaged food);Health food sales;food production;Technology Import and Export;Import and export;Production of hygiene products and single-use medical products(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Novozymes is a world leader in bioinnovation. Novozymes works with its partners to innovate new solutions and rethink industries around the world. Novozymes' industrial enzymes, microorganisms, biopolymers, and other proteins allow its customers to achieve more efficient use of raw materials, reduce energy consumption, replace traditional chemicals with more sustainable alternatives, and offer higher-quality products. Novozymes rethinks everyday products every day.

Yunnan Huazhiliu Health Industry Development Co., Ltd., established on 2020-09-21, Business scope includes licensed projects:Life beauty service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)General project:Health Consulting Services(Does not include medical services);General merchandise sales;food sales(Only sell prepackaged food);Disinfectant sales(Free of Hazardous Chemicals);Domestic trade agent;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Cosmetics Retail;Cosmetics Wholesale;Conference and Exhibition Services;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;software development;business management;marketing planning(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Develops and manufactures drugs related to immunology, neurobiology and oncology

Based on "Quality they trust", Advance Pharmaceutical Inc. develops, manufactures and packages over-the-counter solid dosage pharmaceuticals. For over 25 years, they have built a reputation for delivering the highest quality products, outstanding services and product innovation. The upper management having Master's in Industrial Pharmacy from St.John University, USA with vast practical experiences in the generic pharmaceutical industry brought Advance Pharmaceutical Inc., in a level of quality and trust. Advance Pharmaceutical Inc., follows current Good Manufacturing Practices (cGMP) in all phases of manufacturing as well as Good Laboratory Practices for all tests and evaluations.

Neurimmune Holding AG is a private company headquartered in Schlieren, Switzerland, with domestic subsidiaries, that manufactures pharmaceutical products. The firm was founded in 2006.\nThe company says this about itself: Neurimmune is a biopharmaceutical company translating human immune memory into transformative antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia, dementia with Lewy bodies and ATTR cardiomyopathy. Neurimmune discovered aducanumab, a human monoclonal antibody that removes amyloid beta from brains of patients with Alzheimer's disease, and licensed it to Biogen. With its RTM™ technology, Neurimmune also discovered the anti-miSOD1 antibody AP-101 for ALS and the anti-ATTR antibody NI006 for ATTR cardiomyopathy, programs being currently evaluated in clinical trials. Neurimmune has three additional antibody programs in preclinical development, and has recently expanded the spectrum of its treatment modalities by adding a small molecule program and programs involving vectorized expression of human antibody genes.